Table 1.

Responses to first-line and subsequent systemic therapies for unresectable locoregional or distant recurrence

	Ipilimumab (+/−PD1)	BRAF/MEKi	PD1 monotherapy	PD(L)1 + novel agent**
N	44*	40†	14	11
Recurred ON PD1	38	27	9	10
Recurred OFF PD1	6	13	5	1
Median F/U (months)	8.4	5.5	8.4	6.4
ORR, % (95% CI)$
Total	26 (14–43)	82 (64–93)	18 (2–52)	11 (0–48)
Recurred ON PD1	24 (12–43)	78 (56–93)	0 (0–46)	13 (0–53)
Recurred OFF PD1	40 (5–85)	90 (55–100)	40 (5–85)	0(0–96)
6-month PFS, % (95% CI)	40 (26 – 58)	70 (52 – 93)	26 (10 – 68)	18 (3 – 93)
Median OS‡ (months, 95% CI)	21.3 (17.6-NR)	12.3 (8.7-NR)	NR	5.5 (4.2 - NR)

Abbreviations: PD(L)1, anti-programmed cell death (Ligand) 1 antibodies

^*includes one who was treated on a clinical trial with ipilimumab, nivolumab and IDO-inhibitor and one treated with ipilimumab + TLR9-agonist.

^†38/40 patients had dabrafenib and trametinib, 1 patient had vemurafenib and cobimetinib, 1 patient had encorafenib and binimetinib.

^**PD1 + novel agents included PD1/-LAG3, -PDL1/MEKi, PD1/TLR9-agonist and PD1/IDOi.

^$95% CI for ORR are based on exact binomial test.

Efficacy data (ORR/PFS) by drug in total cohort regardless of line of therapy. ORR reported for each systemic agent and in those who recurred during or following adjuvant PD1.

^‡OS reported for 1^st line therapy only